1,2-dithiolane derivatives
AssigneeThe University of Mississippi
InventorsHarrihar A. Pershadsingh, Mitchell A. Avery
Life of this patent
Estimating the term…
Abstract
This invention provides new thiazolindinedione derivatives and new arylacetic acid derivatives. These compounds are useful for the treatment of certain cardiovascular certain diseases, certain endocrine diseases, certain inflammatory diseases, certain neoplastic (malignant) and non-malignant proliferative diseases, certain neuro-psychiatric disorders, certain viral diseases, and diseases associated with these viral infections as discussed herein.
Claims33
A compound of the formula
- wherein:
- R1 is hydrogen;
- R2 is hydrogen;
- or R1 and R2 together with the sulfurs to which they are bound join to form a 1,2-dithiolane ring;
- X is a member selected from the group consisting of O, NR, C(O)O, OC(O)O and C(O)NR, wherein R is a member selected from the group consisting of hydrogen, optionally substituted (C1-C6)alkyl and optionally substituted aryl;
- Y is a member selected from the group consisting of O, S and NR3, wherein R3 is a member selected from the group consisting of hydrogen and optionally substituted (C1-C6)alkyl;
- R4 is a member selected from the group consisting of hydrogen, halogen, optionally substituted (C1-C6)alkyl and optionally substituted (C1-C6)alkoxy;
- R5 is a member selected from the group consisting of hydrogen and optionally substituted (C1-C6)alkyl;
- n is an integer from 2 to 14;
- m is an integer from 0 to 14;
- and
- q is an integer from 0 to 1, with the proviso that when m is 0 then q is 0.
A pharmaceutical composition comprising a compound of the formula compound of the formula
- wherein:
- R1 is hydrogen;
- R2 is hydrogen;
- or R1 and R2 together with the sulfurs to which they are bound join to form a 1,2-dithiolane ring;
- X is a member selected from the group consisting of O, NR, C(O)O, OC(O)O and C(O)NR, wherein R is a member selected from the group consisting of hydrogen, optionally substituted (C1-C6)alkyl and optionally substituted aryl;
- Y is a member selected from the group consisting of O, S and NR3, wherein R3 is a member selected from the group consisting of hydrogen and optionally substituted (C1-C6)alkyl;
- R4 is a member selected from the group consisting of hydrogen, halogen, optionally substituted (C1-C6)alkyl and optionally substituted (C1-C6)alkoxy;
- R5 is a member selected from the group consisting of hydrogen and optionally substituted (C1-C6)alkyl;
- n is an integer from 2 to 14;
- m is an integer from 0 to 14;
- and
- q is an integer from 0 to 1, with the proviso that when m is 0 then q is 0;
- or a pharmaceutical acceptable salt or solvate thereof;
- and a pharmaceutical acceptable carrier.
A method of treating a PPARγ mediated disease, said method comprising administering to a subject a therapeutically effective amount of a compound of the of the formula
- wherein:
- R1 is hydrogen;
- R2 is hydrogen;
- or R1 and R2 together with the sulfurs to which they are bound join to form a 1,2-dithiolane ring;
- X is a member selected from the group consisting of O, NR, C(O)O, OC(O)O and C(O)NR, wherein R is a member selected from the group consisting of hydrogen, optionally substituted (C1-C6)alkyl and optionally substituted aryl;
- Y is a member selected from the group consisting of O, S and NR3, wherein R3 is a member selected from the group consisting of hydrogen and optionally substituted (C1-C6)alkyl;
- R4 is a member selected from the group consisting of hydrogen, halogen, optionally substituted (C1-C6)alkyl and optionally substituted (C1-C6)alkoxy;
- R5 is a member selected from the group consisting of hydrogen and optionally substituted (C1-C6)alkyl;
- n is an integer from 2 to 14;
- m is an integer from 0 to 14;
- and
- q is an integer from 0 to 1, with the proviso that when m is 0 then q is 0.
Dependencies are inferred from the claim text.